Sanofi Agrees US Autoimmune Drug Deal for Up to $1.9 Billion

Sanofi is buying an immunology drug from Dren Bio, Inc. for up to $1.9 billion, in a deal it said will help it become a leader in the treatment of diseases of the immune system.

The French pharmaceutical company will acquire a bispecific antibody that is currently being tested in non-Hodgkin lymphoma, which is a form of cancer that develops in the lymphatic system — a network of vessels and glands spread throughout the body.

Shares of Sanofi were largely unchanged in early trading in Paris Thursday. The stock is up 23% in the 12 months through Wednesday’s close.

The ...